Pint Pharma
Drug Stores & Pharmacies · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2321 Rosecrans Ave Ste 2200, El Segundo,...Phone Number
(800) 307-6627Website
www.pint-pharma.comRevenue
$47.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Pint Pharma
Pint-Pharma is a community-centric specialty pharmaceutical company focused on providing innovative solutions for patients with rare diseases in Latin America. The company aims to place the patient perspective at the center of its decision-making processes. With a commitment to becoming a leading player in the region, Pint-Pharma emphasizes the importance of community in its operations. Their services are primarily intended for medical professionals.Explore more
Pint Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pint Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Pint Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Pint Pharma recently announced quarterly report
Pint Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Pint Pharma
Check if Pint Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Pint Pharma is spiking on competitors!
Product Launch: Get notified when Pint Pharma launches new products
Funding: Get notified immidiatlly once Pint Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Pint Pharma
Compare insights from companies similar to Pint Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pint Pharma is experiencing very low activity levels compared to other companies in the Retail sector.
What does this means?
Pint Pharma is drawing exceptional interest within the Retail industry, suggesting notable developments or strong market momentum, learn more about Pint Pharma.
Pint Pharma Tech Stack
A closer look at the technologies used by Pint Pharma
See more technologies
Pint Pharma News & Media
Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Mexico
MEXICO CITY--(BUSINESS WIRE)--It is with great pleasure that we announce the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. Hereditary angioedema is a genetic disorder that causes recurrent episodes of sudden and painful swelling of the skin, mucous membranes and submucosal tissues. UPint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil
SÃO PAULO--(BUSINESS WIRE)--It is with great pleasure that we announce the approval by the Brazilian Health Regulatory Agency (ANVISA) of the medication Orladeyo (berotralstat) for the prevention of hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 and older in Brazil. Hereditary angioedema is a genetic disorder that causes recurrent episodes of sudden and painful swelling of the skin, mucous membranes and submucosal tissues. Until recently, treatment options for HAE wEmpaveli is the first treatment for PNH that binds to the complement protein C3.
SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3. PNH is a rare, chronic, and life-threatening blood disease in which uncontrolled complement activation leads to the destruction of red bPharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America
TAIPEI--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with Pint-Pharma GmbH for the registration and promotion of BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV), a rare blood cancer, in Brazil, Argentina, Colombia, Chile, Peru, Ecuador, and Mexico. “Expanding our geographic reach is critical to our mission to addr
Read more news
Top Drug Stores & Pharmacies Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pint Pharma
Sign Up For FreeTo access detailed company insights
Pint-Pharma is a community-centric specialty pharmaceutical company focused on providing innovative solutions for patients with rare diseases in Latin America. The company aims to place the patient perspective at the center of its decision-making processes. With a commitment to becoming a leading player in the region, Pint-Pharma emphasizes the imp... Read More
